AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05515796
Drug: CapeOx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
Trial: NCT04833140
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patch will provide 100mcg of estradiol daily.
Trial: NCT04833140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch will contain no estradiol.
Trial: NCT06119529
Drug: LY3872386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered either IV or SC.
Trial: NCT06119529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered either IV or SC.
Trial: NCT06094140
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
Trial: NCT05741697
Drug: bi-level ventillation
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-invasive mechanical ventilation
Trial: NCT05138562
Drug: Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x placebo capsules, QD
Trial: NCT05138562
Drug: Active Comparator: TU2670 320mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320mg (80mg x 4), QD
Trial: NCT05138562
Drug: Active Comparator: TU2670 240mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg (80mg x 3 + placebo x 1), QD
Trial: NCT05138562
Drug: Active Comparator: TU2670 120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
Trial: NCT01714089
Drug: RNS60 125 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01714089
Drug: RNS60 250 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05550337
Drug: AKLIEF®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream
Trial: NCT05550337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream
Trial: NCT05719961
Drug: INS062 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I: A single dose of 1.2noml/kg is administered.
Trial: NCT06615193
Drug: HDM2005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM2005 will be administered via IV infusion.
Trial: NCT05719961
Drug: HR20014 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part II: Ascending single doses at three dose levels
Trial: NCT06613776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
Trial: NCT06697522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank comparator
Trial: NCT05844787
Drug: MT101-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04291599
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
Trial: NCT04291599
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
Trial: NCT06299605
Drug: Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
Trial: NCT06299605
Drug: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
Trial: NCT06299605
Drug: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
Trial: NCT05590338
Drug: GSK1070806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive GSK1070806
Trial: NCT05590338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo
Trial: NCT05288543
Drug: IPG7236- Single ascending dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state
Trial: NCT06121570
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Trial: NCT06121570
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Trial: NCT06121570
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Trial: NCT05474846
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT04903002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
Trial: NCT06517199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 tab/day for 28 days
Trial: NCT06365047
Drug: 1000 ppm F toothpaste
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT00000730
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05117034
Drug: Nacl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
Trial: NCT04727086
Drug: BP1.3656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
Trial: NCT04727086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily in tablet form.
Trial: NCT04861298
Drug: standard of care for COVID-19 as per the hospital guidelines
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital standard of care treatment for COVID-19
Trial: NCT05191875
Drug: Saccharomyces Boulardii 250 MG
RxNorm normalized name: Saccharomyces boulardii 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory
Trial: NCT05191875
Drug: Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD
Trial: NCT05233085
Drug: AZD4041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral solution of AZD4041 as stated in arm description.
Trial: NCT06329206
Drug: GH2616 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH2616 tablets will be given orally
Trial: NCT05653323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT05690100
Drug: GeliO3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory Gel which has a beneficial role on wound healing
Trial: NCT05236543
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single oral dose only on Day 1 and Day 11.
Trial: NCT04949399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Injection
Trial: NCT06615440
Drug: Alpha blocker
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prazosin will be given to all children with systemic manifestations (orally or by nasogastric tube) at a dose of 30 μg/kg/dose;first repeat dose at 3 h followed by every 6 h till recovery. All patients will be monitored for clinical improvement with vital signs
Trial: NCT06614621
Drug: Maintenance treatment period:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab：20mg/kg或1200mg，IV, Q3W； Apatinib Mesylate Tablets：250mg，P.O，qod
Trial: NCT05009290
Drug: SHR3680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.
Trial: NCT05009290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.
Trial: NCT06613997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 21 consecutive days
Trial: NCT06617455
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05712278
Drug: SAR445419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell suspension, by intraveneous (IV) injection
Trial: NCT05152576
Drug: OnabotulinumtoxinA X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT05152576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT06258408
Drug: BB102 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BB102 tablets will be administered orally once daily(QD).
Trial: NCT06696482
Drug: Placebo 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
Trial: NCT06711289
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the standard of care, the patients received spinal anesthesia. The type and dosage of the local anesthetic were at the discretion of the treating anesthesiologist.
Trial: NCT05343455
Drug: DFD-29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFD-29 (40 mg) extended release capsules
Trial: NCT05343455
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 40 mg capsules
Trial: NCT06144684
Drug: GUB014295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
Trial: NCT01104844
Drug: Full Dose Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
Trial: NCT01104844
Drug: Quarter dose strength
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
Trial: NCT01104844
Drug: Half dose strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
Trial: NCT01104844
Drug: Acetaminophen standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
Trial: NCT01104844
Drug: Ibuprofen low dose
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
Trial: NCT01104844
Drug: Ibuprofen high dose
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
Trial: NCT01104844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets
Trial: NCT05165069
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
Trial: NCT05293158
Drug: Hepatect CP 50 I.E./ml infusion solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection.
Trial: NCT05784155
Drug: Test Drug(JW0302) or Reference Drug(C2206)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Trial: NCT06426654
Drug: sintiliman plus LDRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles.
Trial: NCT06342258
Drug: Ultradent Ultra Seal XT Plus
RxNorm normalized name: Flexall Ultra Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
Trial: NCT05051163
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days of once daily dosing
Trial: NCT05686564
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bis-choline tetrathiomolybdate
Trial: NCT05487417
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
Trial: NCT05795192
Drug: SB17170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking SB17170 orally once a day
Trial: NCT05795192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking Placebo orally once a day
Trial: NCT05011513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablet)
Trial: NCT05011513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (capsule)
Trial: NCT04648046
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-ablative conditioning with cyclophosphamide.
Trial: NCT05099835
Drug: triamcinolonacetonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolonacetonide stellate ganglion injection
Trial: NCT04676399
Drug: Hydrochlorothiazide 12.5mg
RxNorm normalized name: HYDROCHLOROTHIAZIDE 12.5MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
Trial: NCT04676399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
Trial: NCT05494437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06216210
Drug: opioid-FREE anesthesia.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,
Trial: NCT06216210
Drug: opioid-CONTAINING anesthesia.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
Trial: NCT05041270
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
Trial: NCT04713514
Drug: OSE2101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
Trial: NCT06414902
Drug: ArabinoFuranosylGuanine [18F]F-AraG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05478863
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally self-administered by study participants.
Trial: NCT05478863
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC will be orally self-administered by study participants.
Trial: NCT05478863
Drug: Oral CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD will be orally self-administered by study participants.
Trial: NCT05478863
Drug: Oral Caffeine
RxNorm normalized name: caffeine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine will be orally self-administered by study participants.
Trial: NCT05496569
Drug: TQB3616 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
Trial: NCT05496569
Drug: TQB3616 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04610398
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s. arm/group description
Trial: NCT04288193
Drug: Recommendation to Deprescribe
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendation to Deprescribe
Trial: NCT04800237
Drug: VQW-765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT04800237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT05218642
Drug: KX- 826 dosed at 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
Trial: NCT05218642
Drug: Matching placebo to KX-826
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied topically to scalp twice daily or once daily for 24 weeks
Trial: NCT05997927
Drug: VC005 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 groups repeat administration for 12 weeks
Trial: NCT05997927
Drug: VC005 Tablets Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 placebo groups repeat administration for 12 weeks